SAL Trading’s Novo Nordisk NVO Stock Holding History

SAL Trading’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-107,800	Closed	-$5.98M	–	53
2022 Q1	$5.99M	Buy	107,800 +86,800	+413%	+$4.45M	1.39%	15
2021 Q4	$1.18M	Buy	+21,000	New	+$1.14M	0.48%	14

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

SAL Trading's NVO Position: Q2 2022 in Review

SAL Trading sold out of Novo Nordisk (NVO) in Q2 2022, closing a stake of 107,800 shares — an estimated $5.98M sold.

SAL Trading first reported a position in NVO in Q4 2021 and held it in 2 quarters. The position peaked at $5.99M in Q1 2022. 934 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

SAL Trading reported no remaining Novo Nordisk position as of Q2 2022 after selling out during the quarter.
SAL Trading sold 107,800 Novo Nordisk shares in Q2 2022, an estimated $5.98M.
SAL Trading first reported a position in Novo Nordisk in Q4 2021 and held it in 2 quarters.
SAL Trading's Novo Nordisk position peaked at $5.99M in Q1 2022.
934 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on SAL Trading's 13F filing for Q2 2022, filed 15 Aug 2022.